hVIVO plc (OPORF)
OTC Markets OTCPK · USD · Healthcare · Diagnostics & Research
$0.1096 (+0.00%) as of
Key statistics
- Market cap
- 75.45M
- EPS (TTM)
- -0.0100
- Dividend yield
- 0.00%
- 52-week range
- 0.0861 – 0.3500
- Beta
- 1.66
- Revenue (TTM)
- 42.09M
- Profit margin
- -29.01%
- Volume
- 1.00k
About hVIVO plc
hVIVO plc operates as a full-service early specialist contract research organisation in the United Kingdom, Europe, and North America. It provides end-to-end early clinical development services to the biopharmaceutical industry, including phase I capabilities and world leading human challenge trial services. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including virology, immunology and biomarker analysis, as well as assay development, sample analysis, and data interpretation. In addition, the company offers services combined with specialisms in infectious diseases, respiratory, and cardiometabolic therapeutical areas. Further, it provides preclinical and early clinical research services; sales and marketing services; data management; storage solutions; and statistics services, as well as drug development consultancy and services. The company also provides clinical research services, including early-phase trials and human pharmacological studies. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Headquarters
- London, United Kingdom
- Employees
- 376
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.